1229024-57-0
1229024-57-0
Chemical Structure
BBIQ
- CAS No.: 1229024-57-0
- Formula:C21H22N4
- Molecular Weight:330.43
IUPAC Name: 1-benzyl-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine
InChIKey: CQBDMXYZNLJUFT-UHFFFAOYSA-N
SMILES: NC1=NC2=CC=CC=C2C3=C1N=C(CCCC)N3CC4=CC=CC=C4
Biological Activity: BBIQ is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC50 of 59.1 nM for human TLR7. BBIQ is a powerful vaccine adjuvant that enhances innate immune responses[1][2].
| Cat. No. | 상품명 | Purity | 제품 설명 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BBIQ | 99.81% | BBIQ is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC50 of 59.1 nM for human TLR7. BBIQ is a powerful vaccine adjuvant that enhances innate immune responses. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BBIQ (GMP) | BBIQ (GMP) is BBIQ (HY-111582) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. BBIQ is a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC50 of 59.1 nM. BBIQ is a powerful vaccine adjuvant that enhances innate immune responses. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.86
HY-156174E104 -
Similarity Score 0.84
HY-159178m-AM-BBIQ -
Similarity Score 0.84
HY-158694TLR7 agonist 20 -
Similarity Score 0.84
HY-103698TLR7/8 agonist 1 -
Similarity Score 0.82
HY-103698ATLR7/8 agonist 1 dihydrochloride -
Similarity Score 0.81
HY-161726TLR7 agonist 23 -
Similarity Score 0.76
HY-156177TLR7 agonist 16 -
Similarity Score 0.75
HY-156176TLR7 agonist 15 -
Similarity Score 0.69
HY-156175TLR7 agonist 14 -
Explore the MedChemAI to find more analogs
References
- [1]. Saroa R, et al. Efficacy of TLR7 agonistic imidazoquinoline as immunochemotherapeutic agent against P. Berghei ANKA infected rodent host. Bioorg Med Chem Lett. 2019 May 1;29(9):1099-1105. [Content Brief]
- [2]. Kaushik D, et al. BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant. Hum Vaccin Immunother. 2020 Apr 16:1-8. [Content Brief]
